HRT for Perimenopause: What You Need to Know

Few topics in women’s health carry as much confusion as hormone replacement therapy. If you’ve spent time searching online, you’ve likely encountered wildly contradictory information: articles that describe HRT as dangerous sitting alongside posts from women saying it gave them their life back. Clinicians who refuse to prescribe it. Other clinicians who consider it standard of care. It can feel impossible to know what to believe.

Here is what we can tell you with confidence: the evidence on HRT has been extensively studied, debated, re-analyzed, and clarified over the past two decades. The picture is considerably more nuanced than either the fear or the enthusiasm would suggest. This article walks through what the current evidence says, clearly and without hype.

What HRT Actually Is

Hormone replacement therapy, increasingly referred to as menopausal hormone therapy (MHT) in clinical settings, involves supplementing hormones that your body is producing less predictably during perimenopause and less abundantly after menopause.

The most commonly used forms, estradiol and micronized progesterone, are chemically identical to the hormones your body makes, and both come in FDA-approved forms. Identical does not mean risk-free: HRT is a medication with real benefits and real risks, used at a time when your body’s own production is becoming erratic and eventually declining.

During perimenopause, estrogen doesn’t follow a smooth downward slope. As ACOG explains in its menopause years FAQ, it fluctuates wildly, sometimes surging to levels higher than you experienced in your twenties and sometimes dropping sharply. These swings are what drive many of the symptoms women find most disruptive: hot flashes, sleep disruption, mood changes, brain fog, and joint pain. HRT is approved to treat the hot flashes and night sweats these swings can cause, but not mood changes, brain fog, or joint pain.

Types of HRT

There are several components of hormone therapy, and your clinician will recommend a combination based on your symptoms, medical history, and whether you still have a uterus.

Estrogen

Estrogen is the primary component of HRT and the hormone most directly responsible for relieving vasomotor symptoms (hot flashes and night sweats). It comes in several forms:

• Transdermal (patch, gel, spray): Applied to the skin. Generally preferred for patients at higher clotting risk because it bypasses first-pass liver metabolism, which is associated with a lower risk of blood clots than oral forms (NAMS). Common brands include Estradot, Climara (patches), and Estrogel, Divigel (gels).
• Oral (pills): Taken by mouth. Effective, but carries a slightly higher risk of blood clots and may affect triglycerides. Oral estradiol is the most commonly prescribed form.
• Vaginal (cream, ring, tablet): Low-dose, local estrogen that treats vaginal dryness, urinary symptoms, and painful intercourse. Because the dose is low and very little is absorbed into the bloodstream, guidelines support vaginal estrogen for many women who cannot use systemic HRT. It is not risk-free, and anyone with a history of breast cancer should discuss it with their oncology team. It does not typically require progesterone for uterine protection.

Progesterone / Progestins

If you have a uterus, you need progesterone or a progestin alongside estrogen. This is non-negotiable from a safety standpoint because taking estrogen alone (unopposed estrogen) stimulates the uterine lining and significantly increases the risk of endometrial cancer.

• Micronized progesterone (Prometrium): Structurally identical to the progesterone your body produces, and FDA-approved. It can cause drowsiness, so it is usually taken at bedtime. Some observational data suggest it may carry less breast cancer risk than some synthetic progestins, though the evidence is limited.
• Synthetic progestins (medroxyprogesterone acetate, norethindrone): Older forms that are effective for endometrial protection. The WHI study used one of them (medroxyprogesterone acetate, or MPA), not micronized progesterone.
• Hormonal IUD (Mirena): Some clinicians use a levonorgestrel-releasing IUD for uterine protection, which allows you to take estrogen alone. This approach has the advantage of providing contraception (still needed during perimenopause) and delivering a progestin (levonorgestrel) locally rather than systemically.

Testosterone

Testosterone therapy for women is less established than estrogen and progesterone, but evidence supports its use for hypoactive sexual desire disorder (low libido with associated distress) in postmenopausal women. Some clinicians prescribe testosterone off-label for low libido associated with distress, in line with the 2019 Global Consensus Statement. Use for energy or cognitive symptoms is not supported by current consensus guidelines.

There is currently no FDA-approved testosterone product for women in the United States. The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019) supports its use for low sexual desire with associated distress, at doses that maintain blood levels within the normal female range. Any testosterone prescribed for women is off-label, and compounded creams or pellets are not FDA-approved, so dose consistency can vary.

The WHI Study: What Actually Happened

In 2002, the Women’s Health Initiative (WHI) released findings that caused a seismic shift in how HRT was perceived. Headlines reported that hormone therapy caused breast cancer, heart attacks, and strokes. Millions of women stopped their prescriptions overnight. Clinicians stopped prescribing. The effects of that panic persist today, and many women in perimenopause are still afraid to consider HRT, and many clinicians remain reluctant to offer it.

But the story is far more complicated than the headlines suggested.

Here is what matters about the WHI:

• The study population was older. The average age of participants was 63, well past menopause. Many had started HRT 10 or more years after their last period. This is critical because the risks of HRT appear to be significantly influenced by when it’s started.
• The formulation matters. The WHI used conjugated equine estrogens (Premarin, derived from pregnant horse urine) combined with medroxyprogesterone acetate (MPA, a synthetic progestin). These are not the same as the estradiol and micronized progesterone most commonly prescribed today.
• The estrogen-only arm told a different story. Women who took estrogen alone (because they’d had hysterectomies) did not show an increased risk of breast cancer in the trial, though some large observational studies have since found a small increase with longer use. The increased breast cancer risk in the WHI was seen in the combined estrogen-plus-progestin arm, which used MPA.
• Re-analysis tells a different story by age. When the WHI data was re-analyzed by age group, risks looked lower for women who started HRT in their 50s or within 10 years of menopause onset than for women who started later. This is now known as the “timing hypothesis” or “window of opportunity.” HRT is still not recommended to prevent heart disease.

The North American Menopause Society (NAMS), the Endocrine Society, and the International Menopause Society have all issued position statements reflecting this more nuanced understanding: for symptomatic women under 60 or within 10 years of menopause, the benefits of HRT generally outweigh the risks.

This does not mean HRT is risk-free. It means that the 2002 headlines created a level of fear that was not proportionate to the actual evidence, particularly for younger, symptomatic women using modern formulations. For a closer look at the misconceptions that persist, see our article on common myths about perimenopause treatment.

What HRT Treats Effectively

HRT is the most effective available treatment for hot flashes and night sweats. Here is what the evidence shows for the symptoms women ask about most:

• Hot flashes and night sweats: HRT reduces the frequency and severity of vasomotor symptoms by 75–90% in clinical trials, and NAMS recognizes it as the most effective available option.
• Sleep disruption: Some women sleep better on HRT, often because night sweats ease. HRT is not approved as a sleep treatment. Oral micronized progesterone can cause drowsiness, so it is usually taken at bedtime.
• Mood changes: Estrogen may improve mood symptoms in perimenopause for some women, especially alongside hot flashes, but it is not approved to treat depression or anxiety. For clinical depression, antidepressants and therapy are the first-line treatments, and a clinician may consider HRT alongside them.
• Vaginal dryness and urogenital atrophy: Both systemic and local estrogen are approved to treat vaginal dryness and painful intercourse from menopause. Low-dose vaginal estrogen acts mostly locally, and guidelines support it for many women who cannot use systemic HRT. It is not risk-free, and anyone with a history of breast cancer should discuss it with their oncology team.
• Bone density loss: Estrogen is a potent inhibitor of bone resorption. HRT has been shown in randomized trials to reduce the risk of osteoporotic fractures. While not typically prescribed solely for bone protection, this is a meaningful secondary benefit.
• Joint pain: Joint stiffness and aching are common in perimenopause, and some women report that it eases on HRT. HRT is not approved to treat joint pain, and the evidence here is limited.

Who Should Not Use HRT

There are specific medical situations where systemic HRT is contraindicated or requires very careful evaluation:

• Personal history of breast cancer or other estrogen-sensitive cancer
• History of blood clots (deep vein thrombosis or pulmonary embolism)
• Active or recent arterial thromboembolic disease (heart attack, stroke)
• Active liver disease
• Unexplained vaginal bleeding (needs evaluation before starting HRT)
• Known or suspected pregnancy

HRT also carries known risks for women who can use it. Oral estrogen slightly raises the risk of blood clots; observational studies suggest patches and gels carry a lower clot risk, but lower is not zero. Combined estrogen plus progestogen raises breast cancer risk modestly with longer use. Estrogen taken without a progestogen raises the risk of endometrial cancer, which is why women with a uterus who take systemic estrogen also need progesterone or a progestin. In late 2025 the FDA began removing the boxed warnings about cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy labels, with relabeling rolling out product by product. The boxed warning about endometrial cancer remains for systemic estrogen-alone products, and the labels still list these risks and reasons not to use HT.

If you have one of these conditions, it does not necessarily mean you have no options. Non-hormonal treatments exist for most perimenopause symptoms, and vaginal estrogen may still be appropriate for urogenital symptoms. These are conversations to have with a knowledgeable clinician, not decisions to make on your own.

The “Bioidentical” Question

The term “bioidentical hormones” has become a significant source of confusion, largely because it is used as a marketing term as often as it is used as a medical one.

Here is what it actually means: bioidentical describes hormones that are structurally identical to what your body produces. Estradiol is bioidentical estrogen. Micronized progesterone is bioidentical progesterone. “Bioidentical” describes molecular structure, not safety. Both of these are available in FDA-approved, pharmaceutical-grade formulations, meaning they are manufactured to precise standards, with consistent dosing, and have been tested in clinical trials.

When people talk about “bioidentical hormones” as though they are a distinct category of treatment, they are usually referring to compounded hormones, which are custom-mixed formulations prepared by compounding pharmacies. Compounded hormones are sometimes necessary (for example, when a specific dose or combination is not commercially available), but they are not FDA-approved, meaning FDA has not reviewed them for safety or effectiveness, and there is no evidence that they are safer or more effective than FDA-approved options.

Some compounding pharmacies and practitioners market custom compounded hormones as “more natural” or “safer” than conventional HRT. There is no scientific basis for this claim. The FDA, NAMS, and the Endocrine Society have all cautioned against the assumption that compounded means better. Compounded formulations may have inconsistent potency, are not tested in clinical trials, and lack the regulatory oversight applied to pharmaceutical products.

If a clinician recommends compounded hormones, it is reasonable to ask why an FDA-approved bioidentical option would not work equally well.

How to Start: What to Expect

If you and your clinician decide that HRT is appropriate for you, here is what the first few months typically look like:

• Initial evaluation: Your clinician should take a thorough medical history, including personal and family history of breast cancer, blood clots, cardiovascular disease, and liver problems. A baseline mammogram is typically recommended before starting. Blood pressure should be checked.
• Starting doses: Most clinicians begin with a low dose and adjust upward based on symptom response. This “start low, go slow” approach reduces the chance of side effects and helps identify the minimum effective dose.
• First few weeks: Some women experience breast tenderness, bloating, headaches, or mood changes when they start HRT. These side effects usually resolve within the first one to three months as your body adjusts. Breakthrough bleeding or spotting is common in the early months, particularly during perimenopause when your own hormonal fluctuations are still ongoing.
• When you’ll feel a difference: Hot flashes and night sweats often improve within the first two to four weeks. If sleep or mood improves as night sweats ease, that may take slightly longer, typically four to eight weeks. Vaginal symptoms can take three months or more to fully respond. Give it at least three months before making a judgment on effectiveness.
• Follow-up: Plan to check in with your clinician at about three months, then at least annually. Dosing adjustments are common and expected, particularly during perimenopause, when your own hormone levels are still shifting.

How Long Can You Stay on HRT?

This is one of the most frequently asked questions, and the answer has evolved considerably in recent years.

The current NAMS position (2022) recommends using the lowest effective dose for the duration needed to manage symptoms, with periodic reassessment. There is no arbitrary time limit, and the old guideline of “five years maximum” is not supported by current evidence.

For many women, symptoms persist well into their 60s and beyond. Genitourinary symptoms (vaginal dryness, urinary issues) are progressive and lifelong without treatment. The decision about how long to continue HRT should be individualized, weighing ongoing symptom burden against any evolving risk factors.

Some women choose to taper and discontinue, while others continue HRT for decades. Both are legitimate choices when made with informed consent and ongoing clinical oversight.

The Bottom Line

Hormone therapy is neither the reckless choice its critics suggest nor the universal answer its most passionate advocates promote. It is a well-studied medical treatment with clear benefits for specific symptoms, a risk profile that depends heavily on individual factors and timing, and a track record that looks considerably more favorable than the 2002 headlines implied.

For women in their 40s and 50s experiencing significant perimenopause symptoms, HRT deserves a serious, informed conversation, not reflexive fear and not uncritical enthusiasm. For a deeper dive into types, delivery methods, and the window of opportunity, see our comprehensive guide to hormone therapy for perimenopause. The evidence supports that conversation. A knowledgeable clinician can help you navigate it.